Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "A Phase 3 LAGOON Study - Lurbinectedin Alone or in Combination With Irinotecan vs. Investigator's Choice (Topotecan/Irinotecan) for Relapsed SCLC"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Benjamin Besse
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Benjamin Besse
Login to view comments.
Click here to Login